Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

In vitro screening of metabolic clearance using two concentration points.

Williams ET, Farah N, Pelletier RD, Lai WG.

Drug Metab Lett. 2010 Dec;4(4):233-40.

PMID:
20690899
2.

In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Houston JB, Kenworthy KE.

Drug Metab Dispos. 2000 Mar;28(3):246-54. Review.

3.

An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS.

Otten JN, Hingorani GP, Hartley DP, Kragerud SD, Franklin RB.

Drug Metab Lett. 2011 Jan;5(1):17-24.

PMID:
21198441
4.
5.

Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12.

PMID:
12920490
6.

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.

Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, Obach RS.

Eur J Med Chem. 2012 Nov;57:441-8. doi: 10.1016/j.ejmech.2012.06.043. Epub 2012 Jul 16.

PMID:
22840492
7.

Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats.

Chovan JP, Ring SC, Yu E, Baldino JP.

Xenobiotica. 2007 May;37(5):459-73.

PMID:
17523050
8.

Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes.

Duhamel MC, Troncy E, Beaudry F.

Biomed Chromatogr. 2010 Aug;24(8):868-77. doi: 10.1002/bmc.1379.

PMID:
20020418
10.

Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.

Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y.

Drug Metab Dispos. 2001 Oct;29(10):1316-24.

11.

Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.

Baranczewski P, Stańczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H.

Pharmacol Rep. 2006 Jul-Aug;58(4):453-72. Review.

12.

Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H.

Curr Drug Metab. 2010 Oct;11(8):678-85. Review.

PMID:
20973757
13.
14.
16.

Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations.

Jones HM, Houston JB.

Drug Metab Dispos. 2004 Sep;32(9):973-82. Erratum in: Drug Metab Dispos. 2004 Nov;32(11):1331.

17.

Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery.

Klopf W, Worboys P.

Comb Chem High Throughput Screen. 2010 Feb;13(2):159-69. Review.

PMID:
20053167
18.

Applications of high throughput microsomal stability assay in drug discovery.

Di L, Kerns EH, Ma XJ, Huang Y, Carter GT.

Comb Chem High Throughput Screen. 2008 Jul;11(6):469-76.

PMID:
18673274
19.

Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

Shaw PM, Hosea NA, Thompson DV, Lenius JM, Guengerich FP.

Arch Biochem Biophys. 1997 Dec 1;348(1):107-15.

PMID:
9390180
20.

Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.

Stringer RA, Strain-Damerell C, Nicklin P, Houston JB.

Drug Metab Dispos. 2009 May;37(5):1025-34. doi: 10.1124/dmd.108.024810. Epub 2009 Feb 5.

Items per page

Supplemental Content

Write to the Help Desk